Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. - Pohl,G.; Ho,C.L.; Kurman,R.J.; Bristow,R.; Wang,T.L.; Shih Ie,M. (Cancer Res, 2005)